0RN
SULBACTAM
| Created: | 2012-06-11 |
| Last modified: | 2020-06-05 |
Find Related PDB Entry |
|---|
Find related ligands: |
|---|
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 26 |
| Chiral Atom Count | 2 |
| Bond Count | 27 |
| Aromatic Bond Count | 0 |
Chemical Component Summary | |
|---|---|
| Name | SULBACTAM |
| Synonyms | (2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide |
| Systematic Name (OpenEye OEToolkits) | (2S,5R)-3,3-dimethyl-4,4,7-tris(oxidanylidene)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
| Formula | C8 H11 N O5 S |
| Molecular Weight | 233.242 |
| Type | NON-POLYMER |
Chemical Descriptors | |||
|---|---|---|---|
| Type | Program | Version | Descriptor |
| SMILES | ACDLabs | 12.01 | O=S2(=O)C(C(N1C(=O)CC12)C(=O)O)(C)C |
| SMILES | CACTVS | 3.370 | CC1(C)[CH](N2[CH](CC2=O)[S]1(=O)=O)C(O)=O |
| SMILES | OpenEye OEToolkits | 1.7.6 | CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)C |
| Canonical SMILES | CACTVS | 3.370 | CC1(C)[C@@H](N2[C@@H](CC2=O)[S]1(=O)=O)C(O)=O |
| Canonical SMILES | OpenEye OEToolkits | 1.7.6 | CC1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)C |
| InChI | InChI | 1.03 | InChI=1S/C8H11NO5S/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14/h5-6H,3H2,1-2H3,(H,11,12)/t5-,6+/m1/s1 |
| InChIKey | InChI | 1.03 | FKENQMMABCRJMK-RITPCOANSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| DrugBank ID | DB09324 |
|---|---|
| Name | Sulbactam |
| Groups | approved |
| Description | Sulbactam is a beta (β)-lactamase inhibitor and a derivative of the basic penicillin nucleus.[L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296] |
| Synonyms |
|
| Brand Names |
|
| Indication | Sulbactam is used in combination with other antibacterial agents. With [ampicillin], it is used to treat skin and skin structure infections, intra-abdominal infections, and gynecological infections caused by susceptible bacteria.[L50131] In combination with [durlobactam], sulbactam is indicated in adults for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of _Acinetobacter baumannii-calcoaceticus_ complex.[L47336] |
| Categories |
|
| ATC-Code | J01CG01 |
| CAS number | 68373-14-8 |
Drug Targets
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
| Name | Target Sequence | Pharmacological Action | Actions |
|---|---|---|---|
| Beta-lactamase | MKKLIFLIVIALVLSACNSNSSHAKELNDLEKKYNAHIGVYALDTKSGKE... | unknown | inhibitor |
| Solute carrier family 22 member 6 | MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCR... | unknown | substrate |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
| Resource Name | Reference |
|---|---|
| PubChem | 130313 |
| ChEMBL | CHEMBL403 |
| ChEBI | CHEBI:9321 |
| CCDC/CSD | BAFVOT |














